Analyst Price Targets — ALNY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 13, 2026 2:48 pm | — | H.C. Wainwright | $485.00 | $288.08 | TheFly | Alnylam price target raised to $485 from $470 at H.C. Wainwright |
| July 13, 2026 11:08 am | — | Truist Financial | $410.00 | $298.76 | StreetInsider | Alnylam Pharmaceuticals (ALNY) PT Lowered to $410 at Truist SecuritiesMember Login |
| July 10, 2026 12:21 pm | — | Morgan Stanley | $400.00 | $307.42 | TheFly | Alnylam price target raised to $400 from $370 at Morgan Stanley |
| July 9, 2026 3:28 pm | — | Raymond James | $468.00 | $322.64 | TheFly | Alnylam price target raised to $468 from $420 at Raymond James |
| June 29, 2026 9:58 am | — | H.C. Wainwright | $470.00 | $291.37 | TheFly | Alnylam price target lowered to $470 from $510 at H.C. Wainwright |
| May 1, 2026 3:46 pm | — | Morgan Stanley | $370.00 | $301.45 | TheFly | Alnylam price target raised to $370 from $360 at Morgan Stanley |
| May 1, 2026 1:04 pm | — | Bernstein | $447.00 | $302.85 | TheFly | Alnylam price target lowered to $447 from $448 at Bernstein |
| February 17, 2026 12:18 pm | — | Canaccord Genuity | $429.00 | $314.40 | TheFly | Alnylam price target raised to $429 from $415 at Canaccord |
| February 13, 2026 3:40 pm | — | Morgan Stanley | $360.00 | $313.75 | TheFly | Alnylam price target lowered to $360 from $408 at Morgan Stanley |
| February 13, 2026 2:23 pm | — | Bernstein | $451.00 | $312.43 | TheFly | Alnylam price target lowered to $451 from $491 at Bernstein |
Latest News for ALNY
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2026 on Thursday, July 30, 2026, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2026 results as well as expectations for the future via…
I initiate coverage of Alnylam Pharmaceuticals with a non-consensus BUY rating, citing the recent pullback as an overreaction. AMVUTTRA now holds a near-term commercial monopoly in TTR silencing, with strong clinical data and $890 million in Q1 2026 revenue. ALNY's robust cash position ($3.0 billion) and GAAP profitability materially reduce investment risk and support pipeline development.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimer's Association International Conference (AAIC) 2026. This scientific progress underscores the potential of RNAi therapeutics to address the needs of patients with debilitating neurological diseases. Mivelsiran: An…
When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset exposure, pipeline diversification, and the competitive moats protecting established treatments.
CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALNY.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.